Wordt geladen...

Alpelisib-Induced Diabetic Ketoacidosis- A Case Report

Background: Alpelisib, in combination with Fulvestrant, was approved in 2019 by the Food and Drug Administration for treatment of HR+, HER2- advanced or metastatic breast cancer in patients with PIK3CA mutation. a This combination is currently on phase III of study. One of the most common side effec...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Endocr Soc
Hoofdauteurs: Rodriguez, Lisette Patricia, Wiese-Rometsch, Wilhelmine, Lorenzo, Christian
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2021
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090425/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.743
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!